Clinical significance of the expression of activin A in esophageal carcinoma.

Keiji Yoshinaga, Koshi Mimori, Keishi Yamashita, Tohru Utsunomiya, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Activin A is a member of the transforming growth factor beta (TGF-beta) superfamily and is a strong differentiation factor of embryonic stem (ES) cells. It is unknown whether activin A has any correlation with carcinoma cell differentiation. We investigated the expression of activin-betaA (Act-betaA) which is a subunit of activin A, its receptor type I and IIb (ActRI, ActRIIb) and its inhibitor, inhibin-alpha (Inh-alpha), which is a subunit of inhibin A in esophageal carcinoma by reverse transcription polymerase chain reaction (RT-PCR) method. Act-betaA was overexpressed in carcinoma tissues significantly (p=0.030). On the other hand, Inh-alpha, ActRI and ActRIIb were neither overexpressed, nor suppressed. In immunohistochemistry and in situ hybridization analysis, Act-betaA expression was mainly derived from carcinoma cells. The mRNA expression of Act-betaA was not associated with carcinoma cell differentiation but lymph node metastasis (n0, 1, 2 vs. n3, 4; p=0.013) and clinical stage (I, II, III vs. IV; p=0.026). Moreover, patients with high mRNA expression of Act-betaA had a tendency to show poor prognosis compared to those with low mRNA expression (p=0.064). The finding indicated that activin A expression might not be associated with carcinoma cell differentiation but tumor aggressiveness such as lymph node metastasis in esophageal carcinoma.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalInternational journal of oncology
Volume22
Issue number1
Publication statusPublished - Jan 1 2003

Fingerprint

Carcinoma
Cell Differentiation
Messenger RNA
Lymph Nodes
Neoplasm Metastasis
Embryonic Stem Cells
activin A
Transforming Growth Factor beta
Reverse Transcription
In Situ Hybridization
Immunohistochemistry
inhibin beta A subunit
Polymerase Chain Reaction
Neoplasms
inhibin-alpha subunit

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Clinical significance of the expression of activin A in esophageal carcinoma. / Yoshinaga, Keiji; Mimori, Koshi; Yamashita, Keishi; Utsunomiya, Tohru; Inoue, Hiroshi; Mori, Masaki.

In: International journal of oncology, Vol. 22, No. 1, 01.01.2003, p. 75-80.

Research output: Contribution to journalArticle

Yoshinaga, K, Mimori, K, Yamashita, K, Utsunomiya, T, Inoue, H & Mori, M 2003, 'Clinical significance of the expression of activin A in esophageal carcinoma.', International journal of oncology, vol. 22, no. 1, pp. 75-80.
Yoshinaga, Keiji ; Mimori, Koshi ; Yamashita, Keishi ; Utsunomiya, Tohru ; Inoue, Hiroshi ; Mori, Masaki. / Clinical significance of the expression of activin A in esophageal carcinoma. In: International journal of oncology. 2003 ; Vol. 22, No. 1. pp. 75-80.
@article{a991a17a01974117a47ee2eee152fc99,
title = "Clinical significance of the expression of activin A in esophageal carcinoma.",
abstract = "Activin A is a member of the transforming growth factor beta (TGF-beta) superfamily and is a strong differentiation factor of embryonic stem (ES) cells. It is unknown whether activin A has any correlation with carcinoma cell differentiation. We investigated the expression of activin-betaA (Act-betaA) which is a subunit of activin A, its receptor type I and IIb (ActRI, ActRIIb) and its inhibitor, inhibin-alpha (Inh-alpha), which is a subunit of inhibin A in esophageal carcinoma by reverse transcription polymerase chain reaction (RT-PCR) method. Act-betaA was overexpressed in carcinoma tissues significantly (p=0.030). On the other hand, Inh-alpha, ActRI and ActRIIb were neither overexpressed, nor suppressed. In immunohistochemistry and in situ hybridization analysis, Act-betaA expression was mainly derived from carcinoma cells. The mRNA expression of Act-betaA was not associated with carcinoma cell differentiation but lymph node metastasis (n0, 1, 2 vs. n3, 4; p=0.013) and clinical stage (I, II, III vs. IV; p=0.026). Moreover, patients with high mRNA expression of Act-betaA had a tendency to show poor prognosis compared to those with low mRNA expression (p=0.064). The finding indicated that activin A expression might not be associated with carcinoma cell differentiation but tumor aggressiveness such as lymph node metastasis in esophageal carcinoma.",
author = "Keiji Yoshinaga and Koshi Mimori and Keishi Yamashita and Tohru Utsunomiya and Hiroshi Inoue and Masaki Mori",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "22",
pages = "75--80",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Clinical significance of the expression of activin A in esophageal carcinoma.

AU - Yoshinaga, Keiji

AU - Mimori, Koshi

AU - Yamashita, Keishi

AU - Utsunomiya, Tohru

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Activin A is a member of the transforming growth factor beta (TGF-beta) superfamily and is a strong differentiation factor of embryonic stem (ES) cells. It is unknown whether activin A has any correlation with carcinoma cell differentiation. We investigated the expression of activin-betaA (Act-betaA) which is a subunit of activin A, its receptor type I and IIb (ActRI, ActRIIb) and its inhibitor, inhibin-alpha (Inh-alpha), which is a subunit of inhibin A in esophageal carcinoma by reverse transcription polymerase chain reaction (RT-PCR) method. Act-betaA was overexpressed in carcinoma tissues significantly (p=0.030). On the other hand, Inh-alpha, ActRI and ActRIIb were neither overexpressed, nor suppressed. In immunohistochemistry and in situ hybridization analysis, Act-betaA expression was mainly derived from carcinoma cells. The mRNA expression of Act-betaA was not associated with carcinoma cell differentiation but lymph node metastasis (n0, 1, 2 vs. n3, 4; p=0.013) and clinical stage (I, II, III vs. IV; p=0.026). Moreover, patients with high mRNA expression of Act-betaA had a tendency to show poor prognosis compared to those with low mRNA expression (p=0.064). The finding indicated that activin A expression might not be associated with carcinoma cell differentiation but tumor aggressiveness such as lymph node metastasis in esophageal carcinoma.

AB - Activin A is a member of the transforming growth factor beta (TGF-beta) superfamily and is a strong differentiation factor of embryonic stem (ES) cells. It is unknown whether activin A has any correlation with carcinoma cell differentiation. We investigated the expression of activin-betaA (Act-betaA) which is a subunit of activin A, its receptor type I and IIb (ActRI, ActRIIb) and its inhibitor, inhibin-alpha (Inh-alpha), which is a subunit of inhibin A in esophageal carcinoma by reverse transcription polymerase chain reaction (RT-PCR) method. Act-betaA was overexpressed in carcinoma tissues significantly (p=0.030). On the other hand, Inh-alpha, ActRI and ActRIIb were neither overexpressed, nor suppressed. In immunohistochemistry and in situ hybridization analysis, Act-betaA expression was mainly derived from carcinoma cells. The mRNA expression of Act-betaA was not associated with carcinoma cell differentiation but lymph node metastasis (n0, 1, 2 vs. n3, 4; p=0.013) and clinical stage (I, II, III vs. IV; p=0.026). Moreover, patients with high mRNA expression of Act-betaA had a tendency to show poor prognosis compared to those with low mRNA expression (p=0.064). The finding indicated that activin A expression might not be associated with carcinoma cell differentiation but tumor aggressiveness such as lymph node metastasis in esophageal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=1842847888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842847888&partnerID=8YFLogxK

M3 - Article

C2 - 12469187

AN - SCOPUS:1842847888

VL - 22

SP - 75

EP - 80

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -